Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

Midlands/ East Anglia
24 April 2014 16:25



South East (Including East London)
24 April 2014 15:59



Leeds
24 April 2014 15:42


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Joe Moore
Operations Director
joe@zenopa.com
+44 1494 818011

Testimonials
I have nothing but very positive words to say about my experiences working with Zenopa, who have recently recruited me into a new role.
Paul, 2011

Abbott announces acquisition of OptiMedica

16 July 2013 16:27 in Medical Company Restructures


Abbott announces acquisition of OptiMedicaAbbott has announced the acquisition of OptiMedica, a Silicon Valley-based ophthalmic device company, in a move that will expand the firm's presence in the vision care market.

A cash deal worth $250 million (165.78 million pounds) has been agreed to purchase OptiMedica, with additional fees totalling up to $150 million set to be paid upon completion of certain development, regulatory and sales milestones.

This takeover allows Abbott to enter the femtosecond laser-assisted cataract surgery market, giving it control over OptiMedica's Catalys Precision Laser System, which is approved for sale in both the US and Europe.

The global demand for vision care is on the rise and nearly 22 million cataract surgeries will be performed globally in 2013, making this a strategically important acquisition.

Murthy Simhambhatla, senior vice-president for medical optics at Abbott, said: "The Catalys laser system provides physicians with a state-of-the-art, computer-guided alternative in treating patients suffering from cataracts."

Abbott is seeking to expand its portfolio of medical technology assets since refocusing its business earlier this year with the separation of its pharmaceuticals division into the independent company AbbVie.ADNFCR-8000103-ID-801613050-ADNFCR

Other news stories from 16/07/2013

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd